CYSTIC FIBROSIS FOUNDATION

MEDICAL (AND RESEARCH) PROGRAMS - THE CYSTIC FIBROSIS FOUNDATION IS THE WORLD'S LEADER IN THE SEARCH FOR A CURE FOR CYSTIC FIBROSIS, A PROGRESSIVE, GENETIC DISEASE THAT AFFECTS APPROXIMATELY 40,000 PEOPLE IN THE U.S., AND MORE THAN 100,000 WORLDWIDE, WHICH CAN INCLUDE PEOPLE FROM EVERY RACIAL AND ETHNIC GROUP. THE CF FOUNDATION FUNDS HUNDREDS OF MILLIONS OF DOLLARS IN RESEARCH TO HELP DISCOVER/DEVELOP EFFECTIVE CF THERAPIES AND PROMOTE HIGHLY SPECIALIZED CARE, WITH $250 MILLION INVESTED. DUE IN PART TO THE CF FOUNDATION'S EFFORTS, THE LIFE EXPECTANCY OF PEOPLE WITH CF HAS MORE THAN DOUBLED IN THE LAST 30 YEARS. THE CF FOUNDATION FUNDS DISCOVERY AND DEVELOPMENT RESEARCH CONDUCTED BY BIOTECHNOLOGY COMPANIES AND ACADEMIC RESEARCH CENTERS. IT FUNDS A SPECIALIZED CF CLINICAL TRIALS NETWORK OF 91 FOUNDATION-ACCREDITED CARE CENTERS. AS OF DECEMBER 2023, THE CF FOUNDATION DRUG DEVELOPMENT PIPELINE HAD 38 THERAPIES IN DEVELOPMENT INCLUDING TREATMENTS THAT ADDRESS COMPLICATIONS, LIKE INFECTIONS, AND GENETIC THERAPIES THAT COULD ONE DAY LEAD TO A CURE FOR ALL PEOPLE WITH CYSTIC FIBROSIS, INCLUDING THOSE WITH RARE AND NONSENSE DISEASE-CAUSING MUTATIONS. TO SUPPORT ITS MISSION, THE CF FOUNDATION ALSO FUNDS AND ACCREDITS A NATIONWIDE NETWORK OF MORE THAN 130 CARE CENTERS. THIS NETWORK PROVIDES THE BEST CARE FOR PEOPLE WITH CF AND HAS BEEN RECOGNIZED BY THE NATIONAL INSTITUTES OF HEALTH AS A MODEL OF CARE FOR A CHRONIC DISEASE. IN 2023, THE FOUNDATION PROVIDED MORE THAN $49 MILLION FOR CARE CENTERS AND CLINICIANS. THIS WORK INCLUDES DEVELOPING CARE GUIDELINES, FUNDING PROFESSIONAL DEVELOPMENT AWARDS, AND ADVANCING QUALITY IMPROVEMENT OF THE HIGHLY SPECIALIZED CARE NEEDED TO LIVE WITH THE DISEASE. THE CF FOUNDATION ALSO MANAGES A PATIENT REGISTRY OF MORE THAN 32,600 PEOPLE WITH CF, 752 OF WHOM ARE NEWLY DIAGNOSED. THIS INVALUABLE TOOL HELPS IDENTIFY NEW HEALTH TRENDS AND EFFECTIVE TREATMENTS AND IMPROVE THE QUALITY OF CF CARE. THE PATIENT REGISTRY IS AN INTERNATIONALLY RECOGNIZED MODEL FOR OTHER NONPROFIT HEALTH ORGANIZATIONS, INCLUDING OTHER CF ADVOCACY GROUPS.

THE TWO EXECUTIVES LISTED BELOW PARTICIPATE IN A NONQUALIFIED DEFERRED COMPENSATION PLAN, UNDER WHICH INTERESTS ARE FORFEITED BY THE PARTICIPANT IF THE PARTICIPANT VOLUNTARILY TERMINATES EMPLOYMENT PRIOR TO THE DESIGNATED VESTING DATE. INFORMATION REGARDING THE AMOUNT OF PAYMENTS MADE BY THE PLAN DURING THE REPORTING YEAR IS PROVIDED BELOW. NAME: JOHN C. MAHLER JR AMOUNT: $320,595 NAME: MICHAEL P. BOYLE, M.D. AMOUNT: $304,926